Advanced Biomed (NASDAQ:ADVB) Stock Rating Cut to Sell at Wall Street Zen

Advanced Biomed (NASDAQ:ADVB) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings downgraded shares of Advanced Biomed from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, October 8th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Advanced Biomed Price Performance

Shares of Advanced Biomed stock opened at $3.99 on Friday. Advanced Biomed has a one year low of $3.61 and a one year high of $24.23. The stock’s 50-day moving average is $7.55 and its 200 day moving average is $6.45. The firm has a market cap of $6.58 million, a price-to-earnings ratio of 0.97 and a beta of 0.01.

Advanced Biomed (NASDAQ:ADVB) last released its quarterly earnings data on Tuesday, October 13th. The company reported $0.44 earnings per share for the quarter.

About Advanced Biomed

Advanced Biomed Inc is a clinical-stage biopharmaceutical company focused on developing radiopharmaceutical products for the diagnosis and treatment of cancer.

The company’s research is centered on radioligand therapies, which use targeting molecules to deliver radioactive substances directly to cancer cells. Its development programs include products designed to target prostate-specific membrane antigen (PSMA), an established target in prostate cancer.

Advanced Biomed’s programs remain subject to clinical development and regulatory review.